Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MALAT-1 siRNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Subcutaneous, Intratumoral, Intravitreal
01
Overview
MALAT-1 siRNA is a small interfering RNA (siRNA) designed to target and knock down the expression of metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), an oncogenic long non-coding RNA (lncRNA). MALAT1 is highly expressed in various cancers, including triple-negative breast cancer (TNBC), where it plays a role in promoting tumor progression, metastasis, and immune evasion. In laboratory research, transfection of cancer cells with MALAT-1 siRNA has been shown to inhibit cell proliferation, induce the expression of immune ligands like MICA/B, and repress immune checkpoints such as PD-L1 and B7-H4, thereby enhancing the cytotoxic activity of natural killer (NK) cells and CD8+ T lymphocytes. It is primarily used as a research-use-only (RUO) laboratory reagent.
- Other names
- MALAT1 siRNAMALAT-1 siRNAMALAT 1 siRNAmetastasis-associated lung adenocarcinoma transcript 1 small interfering RNA
02
Targets
MALAT1 (Metastasis associated lung adenocarcinoma transcript 1)
Beyond the preview
Go deeper on MALAT-1 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MALAT-1 siRNA.